Kathryn McCollister

In this systematic literature review published in Value in Health, CHERISH Research Affiliates Czarina Behrends and Ahmed Bayoumi, CHERISH staff members Jared Leff, Jazmine Li, and Erminia Fardone, CHERISH investigators Kathryn McCollister, Sean M. Murphy, and Bruce Schackman, and former NIDA summer intern, Weston Lowry, analyzed 16 studies that summarized and identified gaps of economic […]

The economic burden of substance use disorder (SUD) is significant. It encompasses clinical and societal costs such as health care and social services, criminal justice resources, loss of productivity, and premature mortality, and is estimated to cost more than $700 billion per year in the United States. To understand the gravity of these economic costs, […]

Despite evidence that medications for opioid use disorder (MOUD), namely methadone, buprenorphine, and naltrexone, provided at the point of incarceration improve the well-being of the individual and the public, financial and administrative limitations in jail/prison healthcare often serve as barriers to this recommended first-line treatment for OUD. In fact, evidence indicates that more than 80% […]

Naltrexone and buprenorphine are two effective medications for opioid use disorder (OUD). Naltrexone, which is typically given as a monthly extended-release injection (XR-NTX), and daily oral buprenorphine, which is typically combined with naloxone (BUP-NX), are prescribed in outpatient or office-based medical settings. XR-NTX patients, however, need to complete detoxification before starting treatment. Results from a […]

In this systematic review, researchers affiliated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) including CHERISH staff Erica Onuoha and Jared Leff; CHERISH investigators Bruce R. Schackman, Kathryn E. McCollister, and Sean M. Murphy; and CHERISH Advisory Board member Daniel Polsky, identified new studies supporting buprenorphine and methadone as economically advantageous medications for […]

The National Institute on Drug Abuse, or NIDA, considers data harmonization in substance use disorder, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) research a high-priority. Data harmonization allows investigators to synthesize data across independent studies and promote more rigorous and comparable analyses of an intervention, program, or policy. Harmonizing data also ensures that […]

The National Institute on Drug Abuse (NIDA) of the National Institutes of Health has awarded the Center for Health Economics of Treatment Interventions for Substance Use, HCV and HIV (CHERISH) a five-year grant to continue the Center’s activities as a national center of excellence. CHERISH was founded in 2015 as a multi-institutional center for health […]

“Dr. Kathryn McCollister’s input strengthened our application and we look forward to collaborating on this important and timely project that will provide valuable information on both the effectiveness and cost of this mHealth intervention.” Dr. Adam Carrico Approximately 1.6 million US adults used methamphetamine each year from 2015 to 2018, many of whom had co-occurring […]

Although there are several evidence-based cost-effective interventions for people with opioid use disorder (OUD), they are underutilized. Questions remain regarding intervention selection, and cost of service delivery. Simulation modeling offers an opportunity to support decision making to address the syndemic of opioid overdose, HIV, and hepatitis C (HCV). In an article recently published in the International Journal […]

On July 24 2019, the National Institute on Drug Abuse (NIDA) announced twelve grants totaling approximately $155 million for the Justice Community Opioid Innovation Network (JCOIN) as part of the greater NIDA HEAL initiative. JCOIN will establish a network of 10 clinical research institutions, a Methodology and Advanced Analytics Resource Center (MAARC), and a Coordination and Translation Center (CTC) that […]

On April 18, the National Institute on Drug Abuse (NIDA) together with the Substance Abuse and Mental Health Services Administration (SAMHSA) announced research sites in four states will receive funding as part of the Helping to End Addiction Long-term (HEAL) Initiative HEALing Communities Study. Each state will engage stakeholders and researchers across 15 communities in their […]

The intersection of criminal justice-involved populations and people who use substances makes criminal justice outcomes particularly significant for estimating the economic impact of substance use disorder interventions. New National Institute on Drug Abuse (NIDA) HEAL initiative funding opportunities in response to the opioid crisis include integrated studies that will develop, test, and validate evidence-based approaches to preventing […]